Moderna saw its Q1 sales nearly triple to $389m, almost a threefold rise on the same period of 2025, with international markets driving the increase.
FDA approves Pfizer and Arvinas’ breast cancer drug despite underwhelming data
The FDA on Friday approved Pfizer and Arvinas’ drug vepdegestrant for patients with a certain form of breast cancer. But it’s unclear how many will


